BGNE - BeiGene, Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Beijing,
China
Type: Equity
BGNE price evolution
BGNE
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2592.66 | $2793.37 | $3183.27 | |
| Short term investments | $2.6 | |||
| Net receivables | $529.45 | $435.29 | $358.03 | |
| Inventory | $443.26 | $447.35 | $416.12 | |
| Total current assets | $3839.02 | $3907.75 | $4203.41 | |
| Long term investments | ||||
| Property, plant & equipment | $1620.12 | $1505.74 | $1419.36 | |
| Goodwill & intangible assets | $53.72 | $55.17 | $57.14 | |
| Total noncurrent assets | $1873.16 | $1759.93 | $1601.86 | |
| Total investments | $2.6 | |||
| Total assets | $5712.18 | $5667.68 | $5805.27 | |
| Current liabilities | ||||
| Accounts payable | $333.02 | $356.57 | $315.11 | |
| Deferred revenue | $0.3 | |||
| Short long term debt | $869.32 | $846.37 | $710.32 | |
| Total current liabilities | $1938.77 | $1881.69 | $1810.11 | |
| Long term debt | $220.67 | $216.75 | $219.87 | |
| Total noncurrent liabilities | $407.16 | $425.63 | $457.83 | |
| Total debt | $1089.98 | $1063.12 | $930.18 | |
| Total liabilities | $2345.92 | $2307.32 | $2267.95 | |
| Shareholders' equity | ||||
| Retained earnings | -$8333.6 | -$8213.2 | -$7962.05 | |
| Other shareholder equity | -$140.47 | -$131.64 | -$99.45 | |
| Total shareholder equity | $3366.26 | $3360.36 | $3537.33 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3183.27 | $3869.76 | $4376.01 | $1382.26 |
| Short term investments | $2.6 | $665.25 | $2241.96 | $3268.72 |
| Net receivables | $358.03 | $173.17 | $483.11 | $60.4 |
| Inventory | $416.12 | $282.35 | $242.63 | $89.29 |
| Total current assets | $4203.41 | $5207.08 | $7613.88 | $4960.69 |
| Long term investments | $5.28 | $6.88 | $7.75 | |
| Property, plant & equipment | $1419.36 | $955.91 | $705.04 | $448.27 |
| Goodwill & intangible assets | $57.14 | $40.62 | $46.68 | $5 |
| Total noncurrent assets | $1601.86 | $1172.21 | $1032.07 | $640.07 |
| Total investments | $2.6 | $670.53 | $2248.84 | $3276.47 |
| Total assets | $5805.27 | $6379.29 | $8645.95 | $5600.76 |
| Current liabilities | ||||
| Accounts payable | $315.11 | $294.78 | $262.4 | $231.96 |
| Deferred revenue | $0.3 | $255.89 | $407.7 | |
| Short long term debt | $710.32 | $353.01 | $449.49 | $348.91 |
| Total current liabilities | $1810.11 | $1468.53 | $1599.56 | $1075.2 |
| Long term debt | $219.87 | $243.66 | $245.15 | $213.05 |
| Total noncurrent liabilities | $457.83 | $527.41 | $803.41 | $656.32 |
| Total debt | $930.18 | $596.67 | $694.64 | $561.96 |
| Total liabilities | $2267.95 | $1995.93 | $2402.96 | $1731.51 |
| Shareholders' equity | ||||
| Retained earnings | -$7962.05 | -$7080.34 | -$4966.1 | -$3552.75 |
| Other shareholder equity | -$99.45 | -$77.42 | $17.95 | $6.94 |
| Total shareholder equity | $3537.33 | $4383.35 | $6242.99 | $3869.24 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $929.17 | $751.65 | $634.41 | |
| Cost of revenue | $138.13 | $124.94 | $105.83 | |
| Gross Profit | $791.03 | $626.72 | $528.58 | |
| Operating activities | ||||
| Research & development | $454.47 | $460.64 | $493.99 | |
| Selling, general & administrative | $443.73 | $427.43 | $416.55 | |
| Total operating expenses | $898.2 | $888.07 | $912.37 | |
| Operating income | -$107.16 | -$261.35 | -$383.8 | |
| Income from continuing operations | ||||
| EBIT | -$119.14 | -$259.59 | -$367.05 | |
| Income tax expense | $14.48 | $7.72 | $16.78 | |
| Interest expense | -$13.22 | -$16.16 | -$16.27 | |
| Net income | ||||
| Net income | -$120.41 | -$251.15 | -$367.55 | |
| Income (for common shares) | -$120.41 | -$251.15 | -$367.55 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2458.78 | $1415.92 | $1176.28 | $308.87 |
| Cost of revenue | $379.92 | $286.48 | $164.91 | $70.66 |
| Gross Profit | $2078.86 | $1129.45 | $1011.38 | $238.22 |
| Operating activities | ||||
| Research & development | $1778.59 | $1640.51 | $1459.24 | $1294.88 |
| Selling, general & administrative | $1504.5 | $1277.85 | $990.12 | $600.18 |
| Total operating expenses | $3286.59 | $2919.11 | $2450.11 | $1895.9 |
| Operating income | -$1207.74 | -$1789.66 | -$1438.73 | -$1657.68 |
| Income from continuing operations | ||||
| EBIT | -$899.85 | -$2013.52 | -$1422.83 | -$1616.58 |
| Income tax expense | $55.87 | $42.78 | -$25.23 | -$17.67 |
| Interest expense | -$74.01 | -$52.48 | $15.76 | -$2 |
| Net income | ||||
| Net income | -$881.71 | -$2003.82 | -$1413.35 | -$1596.91 |
| Income (for common shares) | -$881.71 | -$2003.82 | -$1413.35 | -$1596.91 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$120.41 | -$251.15 | -$367.55 | |
| Operating activities | ||||
| Depreciation | $24.93 | $25.29 | $23.82 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $130.64 | $88.67 | $92.92 | |
| Total cash flows from operations | -$95.59 | -$308.57 | -$221.64 | |
| Investing activities | ||||
| Capital expenditures | -$109.95 | -$161.25 | -$147.55 | |
| Investments | $2.65 | $104.33 | ||
| Total cash flows from investing | -$2197.29 | -$111.03 | -$209.83 | -$62.58 |
| Financing activities | ||||
| Dividends paid | -$103.71 | |||
| Sale and purchase of stock | $5.56 | $14.79 | $3.36 | |
| Net borrowings | $14.45 | $147.5 | $343.69 | |
| Total cash flows from financing | $1192.65 | $23.02 | $162.29 | $347.05 |
| Effect of exchange rate | -$12.5 | -$5.9 | -$22.44 | $42.27 |
| Change in cash and equivalents | -$2858.28 | -$189.5 | -$378.55 | $105.09 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$881.71 | -$2003.82 | -$1413.35 | -$1596.91 |
| Operating activities | ||||
| Depreciation | $87.67 | $66.28 | $46.46 | $31.79 |
| Business acquisitions & disposals | -$2.02 | |||
| Stock-based compensation | $367.62 | $303.16 | $240.71 | $183.48 |
| Total cash flows from operations | -$1157.45 | -$1496.62 | -$1298.72 | -$1283.46 |
| Investing activities | ||||
| Capital expenditures | -$561.9 | -$325.43 | -$262.94 | -$117.51 |
| Investments | $656.26 | $1546.22 | $955.51 | -$2939.33 |
| Total cash flows from investing | $60 | $1077.12 | $640.66 | -$3168.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $55.71 | $46.96 | $3535.38 | $4325.12 |
| Net borrowings | $360.77 | -$65.94 | $101.53 | $289.6 |
| Total cash flows from financing | $416.48 | -$18.97 | $3636.91 | $5202.83 |
| Effect of exchange rate | -$8.08 | -$69.38 | $14.04 | $18.23 |
| Change in cash and equivalents | -$689.05 | -$507.85 | $2992.88 | $769.23 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.64 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |